Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155955 | 1.00 | ALDH1A1 (0.59) | ALDH1A1MAPTMAPK1KMT2ARAB9A | |
| SCHEMBL28884413 | 1.00 | ALDH1A1 (0.59) | ALDH1A1MAPTMAPK1KMT2ARAB9A | |
| SCHEMBL8939993 | 0.88 | ALDH1A1 (0.64) | ALDH1A1MAPTMAPK1KMT2ARAB9A | |
| SCHEMBL17595505 | 0.85 | MAPK1 (0.59) | ALDH1A1MAPTMAPK1KMT2ARAB9A | |
| SCHEMBL30268729 | 0.83 | MAPK1 (0.58) | ALDH1A1MAPTMAPK1KMT2ARAB9A | |
| SCHEMBL5798484 | 0.83 | MAPK1 (0.58) | ALDH1A1MAPTMAPK1KMT2ARAB9A | |
| SCHEMBL5798482 | 0.83 | MAPK1 (0.58) | ALDH1A1MAPTMAPK1KMT2ARAB9A | |
| SCHEMBL6153732 | 0.83 | MAPK1 (0.58) | ALDH1A1MAPTMAPK1KMT2ARAB9A | |
| SCHEMBL31439891 | 0.82 | ALDH1A1 (0.63) | ALDH1A1MAPTMAPK1RAB9ACA12 | |
| SCHEMBL15857710 | 0.81 | MAPK1 (0.56) | ALDH1A1MAPTMAPK1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215801-A1 | Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates | KANEKA CORPORATION (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1553093-A1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE 1-SUBSTITUTED AMINO-2,3-EPOXYPROPANES, INTERMEDIATES FOR THE SYNTHESIS THEREOF AND PROCESS FOR PREPARATION OF THE INTERMEDIATES | KANEKA CORPORATION (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215801-A1 | Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates | OXER1, RCC2, CBR3 | ALDH1A1 538/4885MAPT 4259/4885MAPK1 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.